The projected value of RNAi therapeutics and technology market is expected to be valued at USD 1,200 million in 2022 and is anticipated to grow at a CAGR of 17% during the forecast period 2022-2035.

RNA interference (RNAi) therapy has gained significant prominence following the recognition of Andrew Fire and Craig Mello with the 2006 Nobel Prize for their groundbreaking discovery of RNA interference technology. The approval of ONPATTRO? in 2018 marked a pivotal moment, propelling the RNAi therapeutics and technology market into a phase of heightened activity. Subsequently, regulatory authorities approved three more RNAi therapies: GIVLAARI? (November 2019), LEQVIO? (October 2020), and OXLUMO? (November 2020), in a chronological sequence. Presently, an extensive clinical landscape is evolving, with over 200 RNAi therapeutics undergoing evaluation across various clinical trials, encompassing a diverse spectrum of disease indications, including potential applications for treating COVID-19. Notwithstanding the promising attributes of RNAi therapy, developers encounter challenges pertaining to the stability and targeted delivery of their therapeutic candidates. In response to these challenges, several companies have pioneered the development of novel RNA interference technology and delivery systems, aiming to ensure the precise delivery of these therapeutic molecules.

These innovative strides have reoriented the focus of therapy developers towards the burgeoning field of RNAi therapeutics and RNA interference technology. Initiatives are actively exploring the considerable potential of these therapeutic modalities in controlling disease-associated gene expression, thereby broadening the scope of precision medicine applications. Furthermore, the safety demonstrated in systemic delivery has expanded the horizons for RNAi therapy applications. The transformative attributes of RNAi therapeutics, characterized by high specificity, efficiency, and long-term gene silencing capabilities, have captured the attention of major pharmaceutical players. Consequently, substantial investments totaling USD 8.5 billion have been injected into the field over the last five years. This financial commitment underscores the industry’s confidence in the potential of RNAi therapeutics. The research community’s dedication is reflected in the prolific publication of over 3,000 articles related to RNAi therapeutics and technologies, accompanied by the filing and granting of over 2,100 patents.

With the ongoing momentum in research activities and technological advancements, the RNAi therapeutics and technology market is poised for a trajectory of steady growth during the forecast period. This trajectory is indicative of the industry’s resilience and commitment to realizing the full potential of RNA interference technology in revolutionizing the biopharmaceutical landscape.

Report Coverage
? A historical overview of RNAi therapeutics, detailing RNA molecules, mechanisms of action, and application areas, while highlighting key advantages and challenges.
? Over 200 RNAi pipeline candidates in various development stages, considering parameters such as phase, target indication, therapeutic areas, and more.
? An overview of players in RNAi therapeutics development, including establishment year, company size, and headquarters, with a logo landscape based on these factors.
? A three-dimensional bubble analysis of key players, evaluating developer and product portfolio strengths in terms of employee count, years of experience, and RNAi molecules.
? Detailed profiles of advanced-stage drug candidates, covering development status, mechanisms, routes of administration, and recent clinical trial results.
? The current market landscape of technology platforms for RNAi therapeutics, considering purposes, types of molecules, and targeted cells/tissues, with brief profiles of key platforms.
? A technology competitiveness analysis, benchmarking RNAi technologies based on supplier power and key technology specifications.
? A potential target indication in various therapeutic areas for companies engaged in RNAi therapeutics development.
? An analysis of completed, ongoing, and planned clinical studies based on parameters like trial registration year, phase, RNAi molecule type, and regional distribution.
? Key opinion leaders (KOLs) in the RNAi therapeutics domain, employing a 2X2 analysis based on their experience and contributions.
? Insights from a detailed patent analysis, covering filed/granted patents related to RNAi therapeutics since 2016, including patent benchmarking and valuation.
? Detailed review around 3,000 peer-reviewed articles on RNAi therapeutics research, considering parameters like publication year, keywords, journals, and funding.
? An analyzes partnerships related to RNAi therapeutics, covering types, years, disease indications, financial details, and active players.
? Detailed investments made by players in RNAi therapeutics from 2016-2021, considering funding types, amounts, RNAi molecule types, and key investors.
? Estimation of the annual clinical and commercial demand for RNAi therapeutics, considering the target patient population in ongoing/planned trials.
? A forecast analysis of the RNAi therapeutics market until 2035, including sales projections and detailed market segmentation.

Key Market Companies
? AgelessRx
? ANOVA Institute for Regenerative Medicine
? Betterhumans
? BioAge Labs
? bioXcellerator
? Cambrian Biopharma
? Gero.ai
? Mayo Clinic
? Rejuvenate Bio
? UT Health San Antonio